Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned

Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and JapanTop-line data from progression free survival (PFS) primary endpoint expected in 2H 2022...
March 03, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Participate at March Investor Conferences

TEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
February 15, 2022 16:05 ET | Source: VBL Therapeutics

VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
February 02, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference

TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
January 18, 2022 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer

CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian...
January 06, 2022 08:10 ET | Source: VBL Therapeutics

VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat...
December 20, 2021 07:30 ET | Source: VBL Therapeutics

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program

VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL...
November 15, 2021 07:30 ET | Source: VBL Therapeutics

VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL...
November 08, 2021 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics to Report Third Quarter Financial Results on November 15

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant...
October 05, 2021 08:00 ET | Source: VBL Therapeutics

VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States

TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective...